Fortunately, with one or two tweaks to policy, affordable weight-loss drugs are within reach
FDA-approved GLP-1 weight loss medications available at Vitercure Wegovy (semaglutide 2.4mg weekly) for chronic weight management Zepbound (tirzepatide weekly) for chronic weight management and sleep apnea Ozempic (semaglutide weekly) for type 2 diabetes management Mounjaro (tirzepatide weekly) for type 2 diabetes management Saxenda (liraglutide 3mg daily) for chronic weight management Rybelsus (oral semaglutide) for type 2 diabetes management Trulicity (dulaglutide weekly) for type 2 diabetes management For a head-to-head comparison, see our guide on Wegovy vs Zepbound vs Mounjaro vs Saxenda
To learn more about GLP-1s or see if they are right for you, get started with a free consultation
Understanding these genetic factors can help your provider contextualize your dose tolerance, anticipated side-effect profile, and whether a gradual or more conservative escalation approach may be preferable for you
The queries for the articles about mechanism of GLP-1RAs in liver disease and the clinical experiments: ((GLP-1RAs[Title/Abstract]) OR (GLP-1R agonists[Title/Abstract]) OR (GLP-1 receptor agonists[Title/Abstract]) OR (GLP-1 receptor[Title/Abstract])) AND ((liver[Title/Abstract]) OR (hepatic[Title/Abstract]) OR (HCC[Title/Abstract]) OR (fibrosis[Title/Abstract]) OR (cirrhosis[Title/Abstract]) OR (NAFLD[Title/Abstract]) OR (MASLD[Title/Abstract])) AND ((inflammation[Title/Abstract]) OR (immun*[Title/Abstract]) OR (T cell[Title/Abstract]) OR (B cell[Title/Abstract]) OR (NK cell[Title/Abstract]) OR (macrophage[Title/Abstract]))
While some preclinical studies suggest direct hepatic effects, the clinical benefits on liver health appear largely mediated through these indirect metabolic improvements
